Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Effect of Stretching Exercises Versus Aerobic Exercises on Preeclampsia

NCT07255677 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-11-30
Last updated
2025-12-01

Condition(s) studied

Preeclampsia

Investigational drug(s) / intervention(s)

Stretching exercises programAerobic exercises programAntihypertensive drugs

Stretching exercises program: Each woman in the first experimental group will follow a supervised stretching exercise program three times per week for six weeks. Sessions will begin with deep breathing warm-up, followed by stretching each target muscle for 10 seconds with 10 seconds relaxation for the first two weeks, 15 seconds stretching and relaxation in weeks three and four, and 20 seconds in weeks five and six. Each stretch will be repeated 10 times per session. After six weeks, women will be instructed to continue these exercises until delivery.

Aerobic exercises program: The second experimental group will follow a supervised aerobic exercise program of mild to moderate intensity (40%-60% HRmax, calculated as 220 minus age). Heart rate will be monitored before and during exercise. The program, conducted three times per week for six weeks, will start with a 5-minute low-speed walking warm-up. In the first two weeks, this will be followed by 10 minutes on a treadmill (King Fitness Model 8000AC), 5 minutes relaxation, 10 minutes on a stationary bike (GRASP93026), and 5 minutes relaxation. In weeks three and four, treadmill and bike sessions will increase to 15 minutes each, with 10 minutes relaxation between. In weeks five and six, treadmill and bike time will increase to 20 minutes, with 15 minutes relaxation between. After six weeks, women will continue these exercises until delivery.

Antihypertensive drugs: All women in both groups will be treated by antihypertensive drugs (labipress) for 6 weeks.

Study summary

The purpose of the study is to compare between the effect of stretching exercises and aerobic exercises on preeclampsia.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria: * Their ages ranged from 20-30 years old. * Their body mass index (BMI) didn't exceed 35 Kg\\m2. * All women primigravida. * All women are complaining of mild preeclampsia. Exclusion Criteria: * Chronic disease (diabetes mellitus, thyroid, hypertension, nephrotic). * Vaginal bleeding. * Placenta previa. * Physical and psychological disorders.

Primary outcome measure(s)

  • Measurement of arterial blood pressure — 6 weeks
    Arterial blood pressure will be measured from the right arm while the woman is in a half-lying position. The measurement will be the mean of three trials. Each woman in both groups will be assessed before and after the six-week treatment period.
  • Measurement of proteinuria — 6 weeks
    Each woman in both groups will be asked to collect a 24-hour urine sample in sterilized glass bottles for measurement of protein levels. This collection will take place before and after the six-week treatment period.

Trial sites (1)

FacilityCityRegionStatus
Cairo University Giza Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07255677 on ClinicalTrials.gov ↗ ← All trials in Egypt